Is Pfizer (PFE) a risky stock?
As of July 21, 2026, Clavix grades Pfizer (PFE) B- for risk, a composite score of 63 out of 100 on an A+ to F scale, which puts PFE in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind PFE's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how PFE scores on each, as of July 21, 2026.
What's moving PFE's risk right now
Company-specific signals Clavix flags behind PFE's current grade, drawn from recent news and filings as of July 21, 2026.
Pfizer's 7% dividend yield is significantly above the S&P 500's 1% and the pharma sector's 1.5% average, signaling that the market is pricing in a meaningful risk of a dividend cu…
Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 1st quarter, Holdings Channel.com repor…
Catch up on this past week's key developments by state from Law360 Real Estate Authority, including attorney reactions to the structural issues at the old Pfizer building in New Y…
What a B- grade means
On the Clavix A+ to F scale, PFE's composite of 63 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell PFE or any security. Grades are risk indicators, not predictions of return. Data may be delayed.